Unique ID issued by UMIN | UMIN000033639 |
---|---|
Receipt number | R000038230 |
Scientific Title | Effect of co-administration of quercetin on the endothelial dysfunction after continuous treatment of nitroglycerin in Japanese volunteers with aldehyde dehydrogenase2 *2 polymorphism: randomized crossover trial |
Date of disclosure of the study information | 2018/08/06 |
Last modified on | 2019/02/04 10:14:11 |
Effect of co-administration of quercetin on the endothelial dysfunction after continuous treatment of nitroglycerin in Japanese volunteers with aldehyde dehydrogenase2 *2 polymorphism: randomized crossover trial
Effect of quercetin on the endothelial dysfunction after nitroglycerine treatment in Japanese volunteers with ALDH2 *2 polymorphism
Effect of co-administration of quercetin on the endothelial dysfunction after continuous treatment of nitroglycerin in Japanese volunteers with aldehyde dehydrogenase2 *2 polymorphism: randomized crossover trial
Effect of quercetin on the endothelial dysfunction after nitroglycerine treatment in Japanese volunteers with ALDH2 *2 polymorphism
Japan |
angina pectoris
Cardiology | Adult |
Others
YES
To determine the effect of co-administration of quercetin, which has antioxidant effect, on the endothelial function after continuous treatment of nitroglycerin in Japanese healthy volunteers with aldehyde dehydrogenase2 (ALDH2) *2 polymorphism
Safety
Relation between ALDH2 polymorphisms and the values of flow-mediated dilation, and oxidative stress (malondialdehyde).
Relation between ALDH2 polymorphisms and blood pressure, pulse rate.
Relation between ALDH2 polymorphisms and the rate of adverse events.
Interventional
Cross-over
Randomized
Individual
Open -but assessor(s) are blinded
No treatment
2
Prevention
Medicine |
nitroglycerin 25 mg/day is transdermally administered for 7 days
nitroglycerin 25 mg/day and quercetin 1000mg/day are administered for 7 days
20 | years-old | <= |
45 | years-old | > |
Male and Female
Japanese healthy volunteers who are older than 20 and younger than 45
Volunteers who have ALDH2 *1/*1 or *2/*2
1.History of cardiovascular disease
2.Severe hepatic or renal dysfunction
3.Volunteers who received other clinical study drug within 30 days
4.Woman who is pregnant or possibly be pregnant
5.History of severe allergy or allergic reaction to the drugs which are used in the present study
6.History of heart disease, glaucoma, peptic ulcer and aspirin-induced asthma
7.volunteers who have smoking habit 3 months before the start of this study
8.On medical treatment (exclude NSAIDs and sleeping pills taken as needed)
9.On medical treatment of phosphodiesterase 5 or agents with guanylate cyclase stimulating effect
10.systolic blood pressure<90 mmHg
11.Body weight <40 kg or >90 kg
12.Not appropriate to this study by other reasons
24
1st name | |
Middle name | |
Last name | Tatsuya Yoshihara |
SOUSEIKAI Fukuoka Mirai Hospital
Clinical Research Center
3-5-1, Kashiiteriha, Higashi-ku, Fukuoka
092-662-3608
tatsuya-yoshihara@lta-med.com
1st name | |
Middle name | |
Last name | Tatsuya Yoshihara |
SOUSEIKAI Fukuoka Mirai Hospital
Clinical Research Center
3-5-1, Kashiiteriha, Higashi-ku, Fukuoka
092-662-3608
tatsuya-yoshihara@lta-med.com
SOUSEIKAI Fukuoka Mirai Hospital, Clinical Research Center
Japan Society for the Promotion of Science
Japanese Governmental office
Graduate School of Medical Sciences, Kyushu Umiversity
NO
医療法人相生会 福岡みらい病院 臨床研究センター
2018 | Year | 08 | Month | 06 | Day |
Unpublished
Completed
2018 | Year | 08 | Month | 03 | Day |
2018 | Year | 08 | Month | 06 | Day |
2018 | Year | 08 | Month | 06 | Day |
2019 | Year | 02 | Month | 04 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000038230